{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:55:19Z","timestamp":1791903319465,"version":"4.3.4"},"reference-count":50,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chronic graft-versus-host disease (GVHD) is less frequent after posttransplant cyclophosphamide (PTCy)\u2013based prophylaxis, but its clinical characteristics and outcomes compared with chronic GVHD after non-PTCy approaches remain understudied. We addressed this through a single-center retrospective study of 1534 consecutive adult transplant recipients (PTCy, n = 477; non-PTCy, n = 1057) who received grafts from matched related or matched\/mismatched unrelated donors. The cumulative incidence of National Institutes of Health (NIH) moderate\/severe chronic GVHD was significantly lower after PTCy (17% vs 46%; P&amp;lt; .001). Among patients with chronic GVHD (PTCy, n = 163; non-PTCy, n = 656), chronic GVHD after PTCy involved fewer organ sites, had lower severity scores, and had less NIH moderate\/severe disease overall. However, this profile did not translate into improved survival. Univariate analysis demonstrated higher nonrelapse mortality (NRM; 24-month NRM, 22% vs 13%; P = .014) for the PTCy group, whereas multivariate analysis showed that NRM was associated with increased age, NIH overall moderate\/severe chronic GVHD severity, prior grade III\/IV acute GVHD, reduced platelet count, and increased bilirubin. Chronic GVHD after PTCy was associated with increased infectious complications despite reduced immunosuppressive (IS) therapy and higher rates of complete IS discontinuation. Overall, PTCy-based prophylaxis was associated with a lower incidence and severity of chronic GVHD, and after adjustment for established prognostic factors, mortality after chronic GVHD diagnosis was comparable to that observed with non-PTCy prophylaxis approaches. Multicenter validation of these findings and novel strategies to mitigate NRM in chronic GVHD are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020655","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:01:47Z","timestamp":1784671307000},"page":"6598-6609","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Chronic graft-versus-host disease after PTCy-based prophylaxis vs non-PTCy prophylaxis"],"prefix":"10.1182","volume":"10","author":[{"given":"Joseph","family":"Pidala","sequence":"first","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7430-2226","authenticated-orcid":false,"given":"Jongphil","family":"Kim","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2003-9653","authenticated-orcid":false,"given":"Jose","family":"Laborde","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Knott","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnakar","family":"Mogili","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Zinn","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Monroe","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Faramand","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Ramlal","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Khimani","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Torres-Luna","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7789-1257","authenticated-orcid":false,"given":"Michael D.","family":"Jain","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia E.","family":"Perez","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmita","family":"Mishra","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1033-1498","authenticated-orcid":false,"given":"Nima","family":"Ghalehsari","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-5870","authenticated-orcid":false,"given":"Omar","family":"Castaneda-Puglianini","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3744-8672","authenticated-orcid":false,"given":"Fabiana","family":"Perna","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nieder","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abu-Sayeef","family":"Mirza","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9945-4381","authenticated-orcid":false,"given":"Hien","family":"Liu","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Ali","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Chellapandian","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0194-7338","authenticated-orcid":false,"given":"Nelli","family":"Bejanyan","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0119-0622","authenticated-orcid":false,"given":"Claudio","family":"Anasetti","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9605-6436","authenticated-orcid":false,"given":"Aleksandr","family":"Lazaryan","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"3","key":"2026101310433778500_bib1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bbmt.2015.10.018","article-title":"Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"22","author":"Arora","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"2026101310433778500_bib2","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.3324\/haematol.2018.192930","article-title":"Patient-reported outcomes and health status associated with chronic graft-versus-host disease","volume":"103","author":"Lee","year":"2018","journal-title":"Haematologica"},{"issue":"17","key":"2026101310433778500_bib3","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala","year":"28 2011","journal-title":"Blood"},{"issue":"4","key":"2026101310433778500_bib4","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.bbmt.2019.10.019","article-title":"Disability related to chronic graft-versus-host disease","volume":"26","author":"Hamilton","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"15","key":"2026101310433778500_bib5","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1182\/blood-2011-03-344390","article-title":"Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH consensus criteria","volume":"118","author":"Arai","year":"2011","journal-title":"Blood"},{"issue":"16","key":"2026101310433778500_bib6","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"2026101310433778500_bib7","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","article-title":"Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT","volume":"124","author":"Cutler","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2026101310433778500_bib8","first-page":"2062","article-title":"Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors","volume":"96","author":"Nash","year":"2000","journal-title":"Blood"},{"issue":"7","key":"2026101310433778500_bib9","first-page":"2303","article-title":"Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation","volume":"92","author":"Ratanatharathorn","year":"1998","journal-title":"Blood"},{"issue":"29","key":"2026101310433778500_bib10","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1200\/JCO.20.00150","article-title":"Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study","volume":"38","author":"Chang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026101310433778500_bib11","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026101310433778500_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kroger","year":"2016","journal-title":"N Engl J Med"},{"issue":"36","key":"2026101310433778500_bib13","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","article-title":"Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation","volume":"35","author":"Soiffer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026101310433778500_bib14","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2352-3026(19)30220-0","article-title":"Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial","volume":"7","author":"Walker","year":"2020","journal-title":"Lancet Haematol"},{"issue":"9","key":"2026101310433778500_bib15","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.bbmt.2011.02.002","article-title":"Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303","volume":"17","author":"Devine","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"2026101310433778500_bib16","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1200\/JCO.21.01755","article-title":"Naive T-cell depletion to prevent chronic graft-versus-host disease","volume":"40","author":"Bleakley","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026101310433778500_bib17","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood-2013-04-495895","article-title":"Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial","volume":"122","author":"Cutler","year":"2013","journal-title":"Blood"},{"issue":"17","key":"2026101310433778500_bib18","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J Clin Oncol"},{"issue":"13","key":"2026101310433778500_bib19","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood.2023022735","article-title":"Chronic graft-versus-host disease: unresolved complication or ancient history?","volume":"144","author":"Pidala","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2026101310433778500_bib20","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.22.00509","article-title":"Ibrutinib for first-line treatment of chronic graft-versus-host disease: results from the randomized phase III iNTEGRATE study","volume":"41","author":"Miklos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026101310433778500_bib21","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood.V72.2.546.546","article-title":"Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation","volume":"72","author":"Sullivan","year":"1988","journal-title":"Blood"},{"issue":"5","key":"2026101310433778500_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/bbmt.2001.v7.pm11400948","article-title":"Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease","volume":"7","author":"Arora","year":"2001","journal-title":"Biol Blood Marrow Transpl"},{"issue":"21","key":"2026101310433778500_bib23","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1182\/blood-2009-02-202937","article-title":"Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease","volume":"113","author":"Martin","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2026101310433778500_bib24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbmt.2011.05.016","article-title":"Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study","volume":"18","author":"Gilman","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"2026101310433778500_bib25","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3324\/haematol.2018.195123","article-title":"A phase II\/III randomized, multicenter trial of prednisone\/sirolimus versus prednisone\/ sirolimus\/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801","volume":"103","author":"Carpenter","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"2026101310433778500_bib26","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2014-03-563544","article-title":"Failure-free survival after initial systemic treatment of chronic graft-versus-host disease","volume":"124","author":"Inamoto","year":"2014","journal-title":"Blood"},{"issue":"22","key":"2026101310433778500_bib27","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"issue":"21","key":"2026101310433778500_bib28","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2026101310433778500_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"2026101310433778500_bib30","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","article-title":"Axatilimab in recurrent or refractory chronic graft-versus-host disease","volume":"391","author":"Wolff","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"2026101310433778500_bib31","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","article-title":"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)","volume":"6","author":"Bolanos-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"25","key":"2026101310433778500_bib32","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bolanos-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"2026101310433778500_bib33","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026101310433778500_bib34","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16","key":"2026101310433778500_bib35","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/bloodadvances.2020001648","article-title":"Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults","volume":"4","author":"Symons","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2026101310433778500_bib36","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.bbmt.2015.03.003","article-title":"Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors","volume":"21","author":"Solomon","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"2026101310433778500_bib37","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2019.10.014","article-title":"Prospective randomized study comparing myeloablative unrelated umbilical cord blood transplantation versus HLA-haploidentical related stem cell transplantation for adults with hematologic malignancies","volume":"26","author":"Sanz","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"2026101310433778500_bib38","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41409-018-0279-1","article-title":"Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide","volume":"54","author":"Sugita","year":"2019","journal-title":"Bone Marrow Transpl"},{"issue":"14","key":"2026101310433778500_bib39","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1182\/bloodadvances.2022007264","article-title":"Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide","volume":"6","author":"Al Malki","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2026101310433778500_bib40","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.2020007535","article-title":"Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial","volume":"137","author":"Fuchs","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2026101310433778500_bib41","first-page":"681","article-title":"Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis","volume":"28","author":"Saliba","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"11","key":"2026101310433778500_bib42","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.bbmt.2020.07.035","article-title":"Differences in graft-versus-host disease characteristics between haploidentical transplantation using post-transplantation cyclophosphamide and matched unrelated donor transplantation using calcineurin inhibitors","volume":"26","author":"Solh","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"2026101310433778500_bib43","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3324\/haematol.2018.202754","article-title":"Disability related to chronic graft -versus-host disease after alternative donor hematopoietic cell transplantation","volume":"104","author":"Fatobene","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"2026101310433778500_bib44","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1182\/blood-2016-09-737825","article-title":"Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide","volume":"129","author":"Kanakry","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2026101310433778500_bib45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41409-023-02178-y","article-title":"Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate\/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation","volume":"59","author":"Chhabra","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"2026101310433778500_bib46","first-page":"817","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2020 highly morbid forms report","volume":"27","author":"Wolff","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"5","key":"2026101310433778500_bib47","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/leu.2012.292","article-title":"Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study","volume":"27","author":"Arora","year":"2013","journal-title":"Leukemia"},{"issue":"24","key":"2026101310433778500_bib48","doi-asserted-by":"crossref","first-page":"6714","DOI":"10.1182\/blood-2010-12-323824","article-title":"Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis","volume":"117","author":"Arora","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2026101310433778500_bib49","first-page":"940","article-title":"Increased infections and delayed CD4(+) T cell but faster B cell immune reconstitution after post-transplantation cyclophosphamide compared to conventional GVHD prophylaxis in allogeneic transplantation","volume":"27","author":"Khimani","year":"2021","journal-title":"Transpl Cell Ther"},{"key":"2026101310433778500_bib50","doi-asserted-by":"publisher","DOI":"10.1101\/2025.02.25.25322901","article-title":"Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant","author":"Siegel","year":"26  2025","journal-title":"medRxiv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6598\/2591912\/blooda_adv-2026-020655-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6598\/2591912\/blooda_adv-2026-020655-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:43:46Z","timestamp":1791902626000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6598\/569792\/Chronic-graft-versus-host-disease-after-PTCy-based"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":50,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020655","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,9,28]]}}}